The Effect of Imiquimod on Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Malignant Melanoma Cell Invasion

Overview

Journal Ann Dermatol

Specialty Dermatology

Date 2014 Jun 27

PMID 24966637

Citations 3

Authors

Jin Young Jung

Hyun Sook Kim

Mi Ryung Roh

Hyo Jin Roh

Sang Yoon Lee

Kee Yang Chung

Affiliations

Soon will be listed here.

Abstract

Background: A number of reports have been published regarding the use of imiquimod for the treatment of melanoma in situ and metastatic melanoma. Essential steps in the process of melanoma invasion and metastasis include degradation of basement membranes and remodeling of the extracellular matrix by proteolytic enzymes, including matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).

Objective: To evaluate the antiinvasive effect of imiquimod in human malignant melanoma cell lines, SK-MEL-2 and SK-MEL-24, in vitro, and to investigate imiquimod-induced changes in the expression of MMPs and TIMPs.

Methods: Invasiveness of melanoma cell lines following imiquimod treatment was evaluated by invasion assays. In order to investigate the mechanism of the anti-invasive effect of imiquimod, mRNA and protein levels of MMP-2, -9, membrane type 1 (MT1)-MMP, TIMP-1, and -2 were assessed by real-time reverse transcription-polymerase chain reaction, gelatin zymography, and western blotting.

Results: Imiquimod treatment decreased in vitro viability of melanoma cells in a concentration-dependent manner. Imiquimod also elicited a concentration-dependent suppression of invasion in both melanoma cell lines. A concentration-dependent decrease in MMP-2 and MT1-MMP protein levels and a concentration-dependent increase in TIMP-1 and -2 protein levels by imiquimod was observed in both melanoma cell lines. However, expression of MMP-9 protein was increased in SK-MEL-2 but decreased in SK-MEL-24 with increasing imiquimod concentrations. Imiquimod elicited alterations in MMPs and TIMPs mRNA levels that parallel the observed changes in protein levels.

Conclusion: Imiquimod may elicit an anti-invasive effect on human melanoma cells by regulating MMPs and TIMPs.

Citing Articles

Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury.

Chen G, Ge D, Zhu B, Shi H, Ma Q J Int Med Res. 2020; 48(4):300060520919592.

PMID: 32339071 PMC: 7219017. DOI: 10.1177/0300060520919592.

Serum markers in early-stage and locally advanced melanoma.

Lugowska I, Kowalska M, Fuksiewicz M, Kotowicz B, Mierzejewska E, Kosela-Paterczyk H Tumour Biol. 2015; 36(11):8277-85.

PMID: 26002577 PMC: 4672018. DOI: 10.1007/s13277-015-3564-2.

Protease-activated receptor 2 agonist increases cell proliferation and invasion of human pancreatic cancer cells.

Xie L, Duan Z, Liu C, Zheng Y, Zhou J Exp Ther Med. 2014; 9(1):239-244.

PMID: 25452809 PMC: 4247309. DOI: 10.3892/etm.2014.2052.

References

Pyke C, Ralfkiaer E, Tryggvason K, Dano K . Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol. 1993; 142(2):359-65. PMC: 1886712. View

Liotta L, Tryggvason K, Garbisa S, Hart I, FOLTZ C, Shafie S . Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284(5751):67-8. DOI: 10.1038/284067a0. View

Butler G, Butler M, Atkinson S, Will H, Tamura T, Schade van Westrum S . The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem. 1998; 273(2):871-80. DOI: 10.1074/jbc.273.2.871. View

Hofmann U, Westphal J, Zendman A, Becker J, Ruiter D, van Muijen G . Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol. 2000; 191(3):245-56. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#. View

Hofmann U, Houben R, Brocker E, Becker J . Role of matrix metalloproteinases in melanoma cell invasion. Biochimie. 2005; 87(3-4):307-14. DOI: 10.1016/j.biochi.2005.01.013. View

Visse R, Nagase H . Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8):827-39. DOI: 10.1161/01.RES.0000070112.80711.3D. View

Hesling C, DIncan M, Mansard S, Franck F, Corbin-Duval A, Chevenet C . In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol. 2004; 150(4):761-7. DOI: 10.1111/j.0007-0963.2004.05898.x. View

Henriet P, BLAVIER L, DeClerck Y . Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS. 1999; 107(1):111-9. DOI: 10.1111/j.1699-0463.1999.tb01533.x. View

Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N . Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 2001; 20(17):4782-93. PMC: 125610. DOI: 10.1093/emboj/20.17.4782. View

10.

van den Oord J, Paemen L, Opdenakker G, De Wolf-Peeters C . Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997; 151(3):665-70. PMC: 1857847. View

11.

Hofmann U, Eggert A, Blass K, Brocker E, Becker J . Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res. 2003; 63(23):8221-5. View

12.

MacDougall J, Bani M, Lin Y, Rak J, Kerbel R . The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res. 1995; 55(18):4174-81. View

13.

Brinckerhoff C, Matrisian L . Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002; 3(3):207-14. DOI: 10.1038/nrm763. View

14.

van Meurs T, van Doorn R, Kirtschig G . Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg. 2007; 33(5):623-6. DOI: 10.1111/j.1524-4725.2007.33129.x. View

15.

Naylor M, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C . Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003; 149 Suppl 66:66-70. DOI: 10.1046/j.0366-077x.2003.05637.x. View

16.

Strongin A, Collier I, Bannikov G, Marmer B, Grant G, Goldberg G . Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995; 270(10):5331-8. DOI: 10.1074/jbc.270.10.5331. View

17.

Finan K, Hodge G, Reynolds A, Hodge S, Holmes M, Baker A . In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer. 2006; 53(3):273-84. DOI: 10.1016/j.lungcan.2006.06.006. View

18.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

19.

Vaisanen A, Kallioinen M, TASKINEN P, Turpeenniemi-Hujanen T . Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1999; 186(1):51-8. DOI: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P. View

20.

Woodmansee C, McCall M . Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatol Surg. 2009; 35(8):1286-9. DOI: 10.1111/j.1524-4725.2009.01227.x. View